A new potentiator of insulin action

Publisher Website
Google Scholar
Abstract
A new potentiator of insulin action, 5‐[4‐(1‐methylcyclohexylmethoxy)‐benzyl]thiazolidine‐2,4‐dione, was tested for activation of insulin action in vitro. The agent (50 mg.kg−1.day−1) was orally administered to rats for 14 days and adipocytes from treated rats were used to assess insulin‐binding, glucose uptake and glucose oxidation. In obese rats, the agent increased glucose uptake and oxidation without any change in insulin binding, whereas in lean or streptozotocin‐treated rats it failed to increase glucose metabolism. Fat tissues were cultured with the agent for 24 h and were tested for insulin action. In the presence of insulin (10 ng/ml) in the culture media, the agent increased glucose oxidation in these cells without any change in insulin binding. However, without insulin in the culture media the agent did not increase glucose oxidation. Thus, the agent appeared to potentiate insulin action at the post receptor process.